Participated · Series B · Aug 2026

Khartis Therapeutics is developing a pipeline of oral small molecule medicines, with a lead program that is an oral selective IGF-1R inhibitor designed for thyroid eye disease. The company is also advancing additional oral small-molecule programs against clinically validated immunology pathways. Khartis was founded in 2024 by Robert Hoffman (CEO and Head of Drug Discovery), Craig Murphy (CSO), and Chris LeMasters (Executive Chairman), and was incubated within Foresite Labs. It is headquartered in San Diego and its team includes many members who previously worked together at XinThera. Financially, Khartis has raised a total of $95 million following its $50 million Series B. The company intends to use the new financing to accelerate advancement of its lead program and continue discovery of differentiated small molecule medicines.

Participated · Series C · May 2026

Accro Bioscience is a clinical-stage biotech developing first- and best-in-class small-molecule therapeutics that target regulatory cell death pathways for inflammatory and immune-mediated diseases. Its lead asset, AC-101, is a selective RIPK2 inhibitor being developed for moderate-to-severe ulcerative colitis and has completed Phase I studies in healthy volunteers in Australia and China, plus a Phase Ib/IIa proof-of-concept study in Chinese patients. The company has received IND clearance from the U.S. FDA to proceed with Phase II studies of AC-101. Accro announced a $50 million Series C to fund a Phase IIb trial of AC-101 and to advance other pipeline candidates. The company operates out of New York and Suzhou and describes a multi-asset pipeline originating from a proprietary drug discovery platform focused on regulatory cell death and inflammation. Ongoing clinical progress and the new financing position Accro to advance global development of its lead and follow-on programs.

Participated · Series D · Apr 2026

Pulnovo Medical develops a Pulmonary Artery Denervation (PADN) system, a minimally invasive interventional therapy targeting over‑activated sympathetic nerve activity implicated in pulmonary vascular remodeling and cardiopulmonary disease progression. Multiple global studies and inclusion in international guidelines (including the 2022 ESC/ERS Guidelines) support PADN’s clinical benefits in improving functional capacity and reducing major adverse events. The company reports approximately 1,500 PADN procedures performed globally and regulatory approvals in seven countries, while actively promoting commercialization in the EU, Middle East, and China. In the U.S., Pulnovo has received FDA Breakthrough Device Designation and launched two fully approved IDE clinical trials led by Professor Gregg Stone. Pulnovo is pursuing further clinical evidence (including the PULSE‑LHD IDE trial) and is expanding its global clinical, regulatory, and commercial footprint, including a commercial cooperation agreement with Medtronic. The recent financing will fund continued clinical R&D, global regulatory filings, international commercialization, and investment in the core technology platform.

Participated · Equity · Apr 2026

Pulnovo Medical develops a proprietary Pulmonary Artery Denervation (PADN) System, a minimally invasive therapy aimed at modulating sympathetic nerve activity implicated in pulmonary vascular remodeling and cardiopulmonary disease progression. The company reports about 1,500 PADN procedures performed globally and regulatory approvals in seven countries, and it is advancing commercialization across the European Union, Middle East, and China. Pulnovo's therapy has been referenced in multiple international clinical guidelines, including the 2022 ESC/ERS Guidelines, and clinical studies are ongoing in Europe and Asia with U.S. IDE trials recently initiated. In the United States the company has received FDA Breakthrough Device designation and has started two fully approved IDE trials, including the PULSE-LHD trial. Following the $100 million strategic financing led by Medtronic, Pulnovo plans to use proceeds to support clinical development, regulatory submissions, international commercialization, and continued technology investment. The company is also expanding its leadership team, hiring a Chief Strategy Officer to strengthen ties with global capital markets and industry partners.

Participated · Series B · Apr 2026

Syneron Bio develops macrocyclic peptide therapeutics using its proprietary, high-throughput Synova™ discovery platform. The company's pipeline is diversified across oncology, autoimmune, metabolic, and rare disease indications. Syneron Bio plans to use the Series B proceeds to further evolve and scale its intelligence-driven Synova™ platform and to accelerate progression of multiple core programs into clinical development. The financing, which strengthened the company's cash position, includes participation from global life-science funds, sovereign wealth, strategic corporates and existing shareholders. Syneron Bio highlights improving platform efficiency and success rates as central to its future discovery and development efforts. The company is headquartered in Beijing.